AG 3340.
D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D001381:Azepines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D015507:Drugs, Investigational / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D006877:Hydroxamic Acids / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors*; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy*; D009930:Organic Chemicals; D011480:Protease Inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001381:Azepines; D015507:Drugs, Investigational; D006877:Hydroxamic Acids; D009930:Organic Chemicals; D011480:Protease Inhibitors; C113282:prinomastat; D008666:Metalloendopeptidases